Navigation Links
Sangui Bio Tech International Inc. - Over 500 Customers: Granulox Sales Ahead of Planning
Date:8/13/2012

WITTEN, Germany, August 13, 2012 /PRNewswire/ --

SastoMed GmbH, global licensee of the Sangui patented wound spray, has submitted the announced report covering the first 100 days of Granulox product sales. The report is available on http://www.sastomed.de. Its results meet and in some parts considerably exceed the expectations which were directed at the joint venture company by SanguiBioTech GmbH as the licenser. SastoMed assumes that the initial investments will have amortized by 2014. Before that already, Sangui will participate in each Euro of revenue in Germany and abroad and will profit by the considerable growth dynamic.

The sales strategy is based on an exemplary assessment of the complex health market the accuracy of which is underpinned by the presented sales progress. Until July 31, the sales force had arranged for almost 4,800 meetings and handed over more than 1,000 samples. After no more than 100 days about 500 customers have been registered as actively purchasing the product. With this customer base SastoMed are ahead of planning. In addition, the sales team is present at most conferences, trade shows or workshops dedicated to wound management. The communication with opinion leaders and the expert public will now be complemented by an extensive advertising campaign in the consumer media and the internet. Still, personal contact and practical experience are decisive to convince the users.  

As had been expected according to the findings of Sangui research and development, impressive documentation of successful wound treatments underline the excellent efficacy of Granulox in everyday health care practice. For some time it had been known among medical researchers that there is a correlation between hypoxia and impeded wound healing. Thanks to its research focus on oxygen Sangui was the first and only company to draw the right conclusions and to develop a hemoglobin based technology which ac
'/>"/>

SOURCE Sangui Bio Tech International Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CE Mark Granted for Wound Spray Based on Sangui Patent
2. Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management
3. Yongye International Announces Second Quarter 2012 Financial Results
4. Yongye International to Report Second Quarter 2012 Financial Results on August 9, 2012
5. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
6. SRI International Researchers Developing Bioadhesive Gel to Protect Women from HIV and HSV Infections
7. Elsevier Launches International Journal for Parasitology: Parasites and Wildlife
8. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
9. Bunker Hill Community College Student Speaks at 2012 BIO International Convention
10. International Probiotics Association Excited To Learn The FDA Has Decided To Issue A New, Revised NDI Draft Guidance
11. Promoting the States Quality of Life, New Jersey Symphony Orchestra to Perform at BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 Regis Technologies announced new ... oncology drug substances. , Regis Technologies is proud to ... Potent Compound Suite (PCS) for 2015. , Regis is ... cGMP facility in Morton Grove, Illinois. The PCS addition ... compounds up to about one kilogram per batch. ...
(Date:2/26/2015)... -- Epic Sciences announced today that President and CEO ... Annual Cowen and Company Health Care Conference on Wednesday, March ... Floor. The conference will be held at the Boston ... is developing diagnostic tests of high clinical utility to ... occur during the course of cancer treatments. From a ...
(Date:2/26/2015)... , Feb. 26, 2015 CytomX, a ... cancer, today announced that Sean McCarthy , D. ... at the upcoming Cowen and Company 35 th ... . Dr. McCarthy,s presentation will take place at 4 ... CytomX Therapeutics CytomX Therapeutics develops Probody™ therapeutics for ...
(Date:2/26/2015)... LONDON , February 26, 2015 ... of subjects into PEACH, the first pivotal trial ... dialysis dependent chronic kidney disease (DD-CKD), has completed ... achieved. PT20, invented by leading UK-based ... licensed by Phosphate Therapeutics, is a novel phosphate ...
Breaking Biology Technology:Regis Extends cGMP Services to Oncology Market 2Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3
... physicists have successfully landed a one-two punch on a ... then dosing its perimeter with a laser beam, to ... standstill. The findings, published in Nature Physics ... special quantum properties and in precision-measurements for nanotechnology. The ...
... N.C., June 17 Pharmaceutical Institute (PI), a leading provider ... today announced the release of a new e-course titled, ... newest addition to the company,s Managed Markets Excellence(TM) ... e-course provides a comprehensive overview of the challenges confronting the ...
... (NYSE: DGX ), the world,s leading provider of ... for its previously announced cash tender offer to purchase up ... of its 5.125% Senior Notes due 2010 and 7.50% Senior ... conditions of the tender offer are described in the Offer ...
Cached Biology Technology:Pharmaceutical Institute Launches New E-Course Focused on Health Policy 2Pharmaceutical Institute Launches New E-Course Focused on Health Policy 3Quest Diagnostics Announces Final Tender Offer Results 2Quest Diagnostics Announces Final Tender Offer Results 3
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ... through 2020. Also, a seven-year historic analysis is provided for these ...
(Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... tumors often fail to respond to promising new medication. ... tumor marker for the development of this resistance. A ... great the chances of success are for chemotherapy. At ... promising brain tumor therapy. Dr. Wolf Mller, senior ...
... first information about how fat causes hypertension have been identified ... identify which obese people and maybe some thin ones ... would work best for them. Medical College of ... PTP1B puts mice at risk for hypertension by interfering with ...
... introduced to the U.S. from Europe and other places, garlic ... new study indicates that eventually, however, its primary weapon ... potent. The study, in Proceedings of the National ... show that evolutionary forces can alter the very attributes that ...
Cached Biology News:Why don't brain tumors respond to medication? 2New information about how fat increases blood pressure could help identify those at risk 2New information about how fat increases blood pressure could help identify those at risk 3Over time, an invasive plant loses its toxic edge 2Over time, an invasive plant loses its toxic edge 3
... APO-BRDU Kit is a two color staining ... cellular DNA to detect apoptotic cells by ... and reagents required for measuring apoptosis in ... for assessing reagent performance; washing, reaction and ...
... The CHEMICON APO-BRDU Kit is ... labeling DNA breaks and total cellular DNA ... The kit contains the instructions and ... including; positive and negative control cells for ...
... PowerPac HV high-voltage power supply, with temperature probe, ... of 5,000 V, 500 mA, and 400 W. ... temperature between 0 and 90 degrees C during ... transfer. Power cord and instructions are provided. Dimensions ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Biology Products: